Aldevron News

Partnership with Harvard Scientists at Mass. Eye and Ear and Mass General Supports AAV Based Gene Therapies to Produce SARS-CoV-2 Vaccine

Aldevron is excited to announce our partnership with MEEI to support its manufacturing of an experimental vaccine for clinical studies for its AAVCOVID vaccine program.

Aldevron-MEEI-Partnership-news-post

We have a long history and a strong relationship with MEEI and Luk H. Vandenberghe, Ph.D., who developed the vaccine program. We are proud that our adeno-associated virus (AAV) expertise and our biologics are supporting this possible life-changing vaccine, which uses an AAV vector to deliver and express the Spike gene of the SARS-CoV-2 virus, causing COVID-19 to elicit an immune response. AAVCOVID is in preclinical development and intends to begin testing in humans later this year.

Read the full press release here.

Topics: Plasmid DNA, Viral Vector Therapeutics, Partnerships, Vaccines